

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/000191

International filing date: 07 January 2005 (07.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 04075001.0
Filing date: 07 January 2004 (07.01.2004)

Date of receipt at the International Bureau: 11 February 2005 (11.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

Europäisches
PatentamtEuropean
Patent OfficeOffice européen
des brevets

- 7. 01. 2005

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04075001.0

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office
Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr.:
Application no.: 04075001.0
Demande no.:

Anmelde tag:
Date of filing: 07.01.04
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Taal, Leendert
Loakendiek 2
7255 NL Hengelo (Gld)
PAYS-BAS
Taal-Vlas, Anita Monique
Loakendiek 2
7255 NL Hengelo (Gld)
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Kit for use in the treatment of lupus and tale and mane eczema

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K35/78

Am Anmelde tag benannte Vertragstaaten/Contracting states designated at date of
filling/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

**KIT FOR USE IN THE TREATMENT OF LUPUS AND TALE AND MANE
ECZEMA**

The present invention relates to a kit comprising six botanic
5 compositions. The invention further relates to a kit for use
in the treatment of disorders in mammals, like humans,
horses, cows, pigs and pets, to its use in the treatment of
lupus, multiple sclerosis or rheumatoid arthritis in humans
or tale and mane eczema in horses and to the use of the kit
10 as a medicament.

Lupus and tale and mane eczema are diseases which are
characterized by a complete derangement of the metabolism in
a human or horse, respectively. This results in an
15 accumulation of homotoxins in the connective tissues located
in the skin of humans or in the tale region or mane region of
horses. However, it may also manifest itself in other parts
of the body, such as internal organs.

The skin of human patients suffering from lupus is often very
20 sensitive to light. In severe cases direct light exposure
should be avoided, ultimately leading to a social isolation
of the patient. Further, it is known that patients suffering
from lupus may have a poorly working liver or kidney due to
progressive attacks of inflammation.

25 Horses suffering from tale and mane eczema feel a constant
itching in the affected places. To alleviate this itching,
horses scratch their affected places on rough surfaces.
However, this scratching leads to severe inflammation of the
affected places and ultimately the horses are no longer
30 capable of functioning normally.

Although, lupus and tale and mane eczema are diseases which
are known for many years, a truly effective cure has not yet

been found. Treatments used at present focus on symptoms, i.e. inflammation, but do not treat the disease itself.

The objective of the present invention is to provide for a
5 medicament which is truly effective for use in the treatment
of lupus and tale and mane eczema.

A first aspect of the present invention relates to a kit comprising:

- 10 - a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus senticosus*, or parts thereof;
- a third composition comprising *Avena sativa*, or
15 parts thereof;
- a fourth composition comprising *Ballota Nigra*, or parts thereof;
- a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof; and

- 20 - a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof.

It is believed that one of the pharmaceutically active compounds in the leaves of *Melissa Officinalis* is rosemary acid. It is further believed that the pharmaceutically active 25 compounds of *Eleutherococcus senticosus* are present in the polyphenol-fraction. Moreover, one of the pharmaceutically active compounds in parts of *Ballota Nigra* is most likely caffeic acid. Further, it is believed that the pharmaceutically active compounds of the roots of *Glycyrrhiza glabra/gan cao* are present in the saponin-fraction and that the pharmaceutically active compounds of the roots *Unicaria Tomentosa* are present in the alkaloid-fraction.

The above mentioned kit of compositions is especially suited for human patients suffering from lupus and horses suffering from tale and mane eczema, although other mammals may also be treated with it. By administering the compositions of the kit to patients, the system-reticulo-endothelial blockade is lifted and the biofeedback restored. This leads to an improvement of the overall physical condition of the patient. It is believed that due to the improvement of the physical condition of the patient, the homotoxins which are present in connective tissue of the body are broken down. This stops the accumulation of homotoxins in the connective tissue, resulting in a halt to the inflammation of the skin and other organs. Due to the overall improvement of the physical condition of patients, the above mentioned kit can also be beneficial for human patients suffering from other diseases than lupus, such as for example multiple sclerosis or rheumatoid arthritis.

In a preferred embodiment of the kit,

- 20 - the first composition comprises a unit dose of 100-1000 mg of leaves of *Melissa Officinalis*, or parts thereof;
- the second composition comprises a unit dose of 100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- 25 - the third composition comprises a unit dose of 100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of 100-1000 mg *Ballota Nigra*, or parts thereof;
- the fifth composition comprises a unit dose of 30 100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;

- the sixth composition comprises a unit dose of 100-1000 mg of the roots of *Unicaria Tomentosa*, or parts thereof.

5 A second aspect of the present invention relates to a kit comprising:

- a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;

10 - a second composition comprising *Eleutherococcus senticosus*, or parts thereof;

- a third composition comprising *Avena sativa*, or parts thereof;

- a fourth composition comprising roots of *Piper methysticum*, or parts thereof;

15 - a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;

- a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof.

It is believed that one of the pharmaceutically active 20 compounds in the leaves of *Melissa Officinalis* is rosemary acid. It is further believed that the pharmaceutically active compounds of *Eleutherococcus senticosus* are present in the polyphenol-fraction. Moreover, one of the most important pharmaceutically active compounds in the roots of *Piper methysticum* is most likely resine. Further, it is believed 25 that the pharmaceutically active compounds of the roots of *Glycyrrhiza glabra/gan cao* are present in the saponin-fraction and that the pharmaceutically active compounds of the roots *Unicaria Tomentosa* are present in the alkaloid-fraction.

30 The above mentioned kit is especially suited for the treatment of horses, however other mammals may also be treated with it. It is believed that administering the

compositions of the kit lifts the system-reticulo-endothelial blockade and restores the biofeedback. This leads to an improvement of the overall physical condition of the horse.

Due to the improvement of its physical condition, the

5 homotoxins that cause the itching are broken down. This prevents the homo-toxins from accumulating in the connective tissue of the tale and mane region, resulting in less or no itching.

In a preferred embodiment of the kit of the present

10 invention;

- the first composition comprises a unit dose of 100-1000 mg leaves of Melissa Officinalis, or parts thereof;

- the second composition comprises a unit dose of 100-1000 mg of Eleutherococcus senticosus, or parts thereof;

15 - the third composition comprises a unit dose of 100-1000 mg of Avena sativa, or parts thereof;

- the fourth composition comprises a unit dose of 100-1000 mg roots of Piper methysticum, or parts thereof;

- the fifth composition comprises a unit dose of 20 100-1000 mg roots of Glycyrrhiza glabra/gan cao, or parts thereof.

- the sixth composition comprises a unit dose of 100-1000 mg roots of Unicaria Tomentosa, or parts thereof.

25 In a preferred embodiment of the above mentioned kits, a composition comprises a pharmaceutically acceptable carrier. Moreover, it is preferred if a composition is in the form of a capsule or tablet, although a liquid or sachet may also be used.

30 A third aspect of the present invention relates to a kit as described above for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets.

A fourth aspect of the present invention relates to a kit as described above for use in the treatment of lupus, multiple sclerosis or rheumatoid arthritis in humans or tail and mane eczema in horses.

5 A last aspect of the present invention relates to the use of a kit as described above as a medicament.

The invention will be described by the following examples.

These examples are given for illustration purposes and are

10 not intended to limit the scope of the invention.

EXAMPLES

Example 1

A Spanish female patient suffering from lupus was treated
5 with the compositions of the kit of the present invention.
Before treatment the patient had a poor working liver and was
very sensitive to light. Exposure to light caused several
inflammatory places on the skin. During 5 months the patient
was treated with the compositions of the kit of the
10 invention. She was administered:
- three times a day two capsules containing 210 mg of leaves
of *Melissa Officinalis*;
- three times a day two capsules containing 250 mg of
Eleutherococcus senticosus;
15 - three times a day two capsules containing 250 mg of *Avena*
sativa.
- three times a day one capsule containing 150 mg of an
extract of *Ballota nigra*;
- three times a day two capsules containing 250 mg parts of
20 the roots of *Glycyrrhiza glabra/gan cao*; and
- three times a day one capsule containing 350 mg parts of
roots of *Unicaria Tomentosa*.
After 6 months the patient was exposed to day-light and no
inflammation of the skin took place. Further, MRI-pictures
25 were taken form the liver and they showed that the dark
spots, indicating a poorly working liver, had disappeared.

Example 2

A group of 102 horses (98 Fjords, 2 Icelanders and 2 Half
30 lings) suffering from tale and mane eczema were treated with
the compositions of the kit of the present invention. Before
treatment the horses had several infections in the tale and

mane region. During a period varying from 1 to 6 months the horses were administered:

- three times a day two capsules containing 210 mg of leaves of *Melissa Officinalis*;
- 5 - three times a day two capsules containing 250 mg of *Eleutherococcus senticosus*;
- three times a day two capsules containing 250 mg of *Avena sativa*;
- three times a day two capsules containing 300 mg parts of 10 the roots of *Piper methysticum*;
- three times a day two capsules containing 250 mg parts of the roots of *Glycyrrhiza glabra/gan cao*;
- three times a day one capsule containing 350 mg parts of the roots of *Unicaria Tomentosa*.
- 15 Within a period of six months the conditions of all the horses were evaluated. Seventy nine horses did no longer suffer from tale and mane eczema. Twelve horses showed improvement, although the tale and mane eczema was not cured completely. Eleven horses showed no improvement. It is 20 believed that the disease has affect these eleven horses beyond a biological border, making treatment fruitless.

CLAIMS**1. Kit comprising:**

- a first composition comprising leaves of
5 *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus*
senticosus, or parts thereof;
- a third composition comprising *Avena sativa*, or
parts thereof;
- 10 - a fourth composition comprising *Ballota Nigra*,
or parts thereof;
- a fifth composition comprising roots of
Glycyrrhiza glabra/gan cao, or parts thereof; and
- a sixth composition comprising roots of
15 *Unicaria Tomentosa*, or parts thereof.

2. Kit according to claim 1, wherein

- the first composition comprises a unit dose of
100-1000 mg of leaves of *Melissa Officinalis*, or parts
thereof;
- 20 - the second composition comprises a unit dose of
100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- the third composition comprises a unit dose of
100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of
25 100-1000 mg *Ballota Nigra*, or parts thereof;
- the fifth composition comprises a unit dose of
100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or
parts thereof;
- the sixth composition comprises a unit dose of
30 100-1000 mg of the roots of *Unicaria Tomentosa*, or parts
thereof.

3. Kit comprising:

- a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus senticosus*, or parts thereof;
- 5 - a third composition comprising *Avena sativa*, or parts thereof;
- a fourth composition comprising roots of *Piper methysticum*, or parts thereof;
- a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;
- 10 - a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof.

4. Kit according to claim 3, wherein

- the first composition comprises a unit dose of 15 100-1000 mg leaves of *Melissa Officinalis*, or parts thereof;
- the second composition comprises a unit dose of 100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- the third composition comprises a unit dose of 100-1000 mg of *Avena sativa*, or parts thereof;
- 20 - the fourth composition comprises a unit dose of 100-1000 mg roots of *Piper methysticum*, or parts thereof;
- the fifth composition comprises a unit dose of 100-1000 mg roots of *Glycyrrhiza glabra/gan cao*, or parts thereof.
- 25 - the sixth composition comprises a unit dose of 100-1000 mg roots of *Unicaria Tomentosa*, or parts thereof.

5. Kit according to any of the claims 1-4, wherein a composition comprises a pharmaceutically acceptable carrier.

6. Kit according to claim 1-5 wherein a composition 30 is in the form of a capsule or tablet.

7. Kit according to any of the claims 1-6 for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets.

11

8. Kit according to any of the claims 1-6 for use in
the treatment of lupus, multiple sclerosis or rheumatoid
arthritis in humans or tale and mane eczema in horses.

9. Use of a kit according to claim 1-6 as a
5 medicament.

ABSTRACT

The invention relates to a kit comprising:

- 5 - a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus senticosus*, or parts thereof;
- a third composition comprising *Avena sativa*, or
- 10 parts thereof;
- a fourth composition comprising *Ballota Nigra*, or parts thereof;
- a fifth composition comprising the roots of *Glycyrrhiza glabra/gan cao*, or parts thereof; and
- 15 - a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof. To the kit for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets. To the kit for use in the treatment of lupus, multiple sclerosis or rheumatoid arthritis in humans
- 20 or tale and mane eczema in horses, and to its use as a medicament.